Methyl 4-(Bromomethyl)-3-Methoxybenzoate CAS 70264-94-7 Zafirlukast Intermediate

Short Description:

Name: Methyl 4-(Bromomethyl)-3-Methoxybenzoate

CAS: 70264-94-7

Assay (HPLC): ≥98.0%

Appearance: Pale Yellow Powder

Intermediate of Zafirlukast (CAS 107753-78-6) Antiasthmatic

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply, High Purity, Commercial Production
Chemical Name: Methyl 4-(Bromomethyl)-3-Methoxybenzoate
CAS: 70264-94-7

Chemical Properties:

Chemical Name	Methyl 4-(Bromomethyl)-3-Methoxybenzoate
Synonyms	4-(Bromomethyl)-3-methoxybenzoic Acid Methyl Ester; Methyl 4-(Bromomethyl)-m-anisate; 4-(Bromomethyl)-m-anisic Acid Methyl Ester
CAS Number	70264-94-7
CAT Number	RF-PI437
Stock Status	In Stock
Molecular Formula	C10H11BrO3
Molecular Weight	259.10
Melting Point	92.0 to 94.0℃
Density	1.432
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Pale Yellow Powder
Assay / Analysis Method	≥98.0% (HPLC)
Loss on Drying	≤1.0%
Residue on Ignition	≤0.50%
Total Impurities	≤2.0%
Heavy Metals	≤20ppm
Test Standard	Enterprise Standard
Usage	Intermediate of Zafirlukast (CAS: 107753-78-6), Used as an antiasthmatic

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

Methyl 4-(Bromomethyl)-3-Methoxybenzoate (CAS 70264-94-7) is used as an intermediate of Zafirlukast (CAS: 107753-78-6). Zafirlukast is a highly selective and long-acting oral lys-LTs antagonist. Leukotrienes play an important role in the pathogenesis of asthma. These substances are peptides, being capable of selectively binding to LTC4, LTD4 and LTE4 receptor for antagonism of its effect, reducing the symptoms of asthma and improving lung function. This product is both a preventive agent of inflammation caused by asthma (being antagonistic to leukotriene proinflammatory activity) and a relief drug for bronchial asthma (be antagonistic to leukotriene induced bronchial smooth muscle contraction). The use of this product does not change the smooth muscle response to β2 receptors and has good efficacy in the treatment of bronchoconstriction caused by antigen, aspirin, exercise and cold air, being able to reduce the dosage of hormone and β2 receptor agonist.